Tag: pharma challenges

Bulk drug industry needs to be strengthened’

There is a need to look at strengthening development of the bulk drug industry in India as the country offers tremendous potential in research and development, a senior government official said at the  5th India Pharma Summit.  MUMBAI: There is a need to look at strengthening development of the bulk drug industry in India as the… Read More ›

FDI in pharma doubled during April to December

The government had cleared a Rs 5,168 crore proposal of US-based pharma firm Mylan Inc’s to acquire Indian generic drugs company Agila Specialties.  NEW DELHI: Foreign direct investment in the pharma sector has more than doubled to $1.26 billion during the April-December period of 2013-14 fiscal amid concerns over increasing acquisitions of domestic firms by… Read More ›

Small drug firms fear margin erosion will impact long-term growth

As most pharmaceutical companies have recently agreed to revert to the old trade margins for drugs listed under theDrug Price Control Order (DPCO), the move can come as a major blow for small and medium-sized drug firms, which expect erosion in margins as a result. This leaves SME drug makers strapped for cash, jeopardising their chances of diversifying into… Read More ›

Free pharmacy store, convergence block inaugurated at AIIMS

NEW DELHI: Out-patients at AIIMS will be able to get free generic drugs from tomorrow, thanks to a pharmacy store that opened on its campus today. Union Health Minister Ghulam Nabi Azad inaugurated a ‘Free Generic Pharmacy Store’ and a multi-storied Convergence Block that will house departments from the academics as well the hospital. “Some… Read More ›

Success strategies for Indian pharma industry in an uncertain world

The Indian pharmaceutical industry is going through a period of significant volatility and uncertainty, requiring companies to re-visit their traditional growth strategies to succeed Fragmented Indian pharmaceutical market is facing high volatility and uncertainty. Increasing number of drugs in National List of Essential Medicines (NLEM) and price controls, changing FDI Policy, compulsory licensing, aggressive acquisition investments by… Read More ›

Pharma sales in India to touch $27 bn by 2016: Deloitte

Pharmaceutical sales in India are expected to rise by 14.4 per cent to $27 billion in 2016 from last year, but the life sciences and health care industry is up against challenges such as quality management and meeting global standards, says a report. According to “2014 Global Life Sciences Outlook” by consultancy firm Deloitte, pharmaceutical sales in India stood… Read More ›

Pharma sector battling with fraud among job applicants: Report

MUMBAI: It’s not just the US Food & Drug Administration (US FDA) that the Indian pharmaceutical sector is wary of, but it has a rather unusual problem to deal with back home. A staggering 35 out of every 100 job applicants in the pharmaceutical or clinical trial space are lying about their credentials either by… Read More ›

India raises concerns over FDA actions on domestic drug firms

NEW DELHI: India today raised serious concerns over the USFDA’s audit inspections of Indian pharma companies and ‘disproportionate penalties’ in some instances and said it would submit a discussion document on the issues to the US. The matter came up during a meeting here between Commerce and Industry Minister Anand Sharma and US Food and… Read More ›

US trade enforcement action likely against India, pharma companies to be hit

The U.S. trade representative on Monday will announce a trade enforcement action tied to India, his office said, a move that could further rile relations after an incident last year involving the arrest and strip-search of an Indian consul. U.S. Trade Representative Michael Froman will discuss the action at a news conference at 2 p.m…. Read More ›

Pharma exports to overtake domestic sales in FY15: India Ratings & Research

MUMBAI: India Ratings & Research has revised its outlook on the pharmaceuticals sector for next fiscal to positive from stable on the back of increased exports. The domestic pharmaceutical market is likely to see high single-digit revenue growth. Profit margins are likely to improve on improved utilisation of manufacturing facilities, the rating agency said in its ‘2014 Outlook:… Read More ›